Upgrade to SI Premium - Free Trial

Amgen (AMGN) Announces New Data Evaluating Novel Investigational KRAS(G12C) Inhibitor in Larger Patient Group at WCLC

September 9, 2019 6:20 AM
(Updated - September 9, 2019 6:29 AM EDT)Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles